Welcome to our dedicated page for Femto Technologies news (Ticker: BCAN), a resource for investors and traders seeking the latest updates and insights on Femto Technologies stock.
BYND Cannasoft Enterprises Inc. (BCAN), now identified in SEC filings as Femto Technologies Inc., reports developments tied to its Israeli software and technology businesses. Company news has covered Benefit CRM for small and medium-sized enterprises, a New Cannabis CRM platform for the medical cannabis industry, cannabis-related licensing and facility activity, and EZ-G, a device and capsule system for controlled delivery of low-concentration CBD oils.
Recurring updates include public offerings and registered direct financings, intellectual-property filings for EZ-G through Zigi Carmel Initiatives and Investments, medical-cannabis licensing, EZ-G manufacturing preparations, governance matters, and operating and financial results.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) announced a consulting agreement with Matrix Medika to aid in the regulatory approval process for its EZ-G device. This device is a CBD-based therapeutic product aimed at the female reproductive system. Matrix Medika will provide expert opinion and market research to streamline the development process. Following the acquisition of Zigi Carmel Initiatives, BYND plans to finalize patent registration and implement a marketing strategy for the EZ-G device, focusing on both B2B and B2C sales.
BYND Cannasoft Enterprises (NASDAQ: BCAN) has received initial approval from Israel's Medical Cannabis Unit to engage in medical cannabis without direct contact with the product. This approval is part of the process for obtaining a full license to trade medical cannabis products through a licensed grower in Israel. The Israeli market has about 150,000 medical cannabis users and generates around $0.5 billion annually. BYND aims to capture 3% of this market, equating to approximately $15 million in sales within the first year of product launch.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) has announced an agreement to raise up to CAD$649,500 through a non-brokered private placement. The company plans to issue 150,000 common shares at a price of $4.33 each, with the proceeds earmarked for marketing and public relations expenses. The private placement is set to close by the end of October, pending regulatory approvals, and shares will be subject to a four-month hold period. This move aims to boost visibility and value for shareholders, according to CEO Yftah Ben Yaackov.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) announced a collaboration with the Weizmann Institute of Science to use its beta software as a service (SAAS). This includes BYND's C.R.M. System - Job Management (BENEFIT) and the CANNASOFT module for managing diverse crops. The Weizmann Institute will utilize the software free of charge for one year, after which they have the option to extend the agreement. The partnership aims to advance medical cannabis software development and generate additional revenue from software licenses.
BYND Cannasoft Enterprises (NASDAQ: BCAN) has successfully acquired Zigi Carmel Initiatives & Investments Ltd. by issuing 7,920,000 common shares valued at $37.5 million. This acquisition marks a significant step for BYND as Carmel Zigdon, the new director, is the inventor of the EZ-G device, now being commercialized. The shares allocated to Carmel are subject to a trading hold until January 23, 2023. This strategic acquisition aims to bolster BYND's market position and enhance its software offerings in the cannabis sector.
BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) discusses its operations and future outlook in a recent interview. CEO Yftah Ben Yaackov highlights the company's strategic pivot to enhance its customer relationship management (CRM) software tailored for the medical cannabis market. The company is finalizing a software solution for medical cannabis growers and has acquired a patent-pending CBD treatment device in a significant $28 million transaction. Ben Yaackov emphasizes expected growth through software development and regulatory advancements in the upcoming year.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) has entered a share purchase agreement to acquire Zigi Carmel Initiatives & Investments Ltd. (ZC), gaining ownership of a patent-pending CBD-based therapeutic device targeting women's health. The acquisition involves issuing 7,920,000 shares at $4.735 each and a $100,000 payment for legal expenses. The device aims to alleviate various women's health issues and is projected to enter a market expected to reach $11 billion by 2027. The transaction is set to close by October 10, 2022, pending customary conditions.
BYND Cannasoft Enterprises (NASDAQ: BCAN) has announced its acquisition of Zigi Carmel Initiatives & Investments Ltd. for 100% ownership, granting them the patent pending for the EZ-G device, designed to treat women's health issues through low-concentration CBD oils.
The transaction involves issuing 7,920,000 common shares at $4.735 each, along with a $100,000 payment for legal expenses. The company aims to finalize this acquisition by October 10, 2022, and plans to pursue regulatory approvals, patent registration, and market a unique product to address various female health concerns.